A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 7 months later Aug 4, 2026 → Mar 23, 2028
See other at-risk trials from Novo Nordisk

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 4, 2026 to Mar 23, 2028
    • Study completion moved earlier from Aug 31, 2028 to Mar 23, 2028
    • Study sites revised (75)
    v7
  2. Site details revised at 4 of 75 sitesv6
  3. Study sites revised (75)v5
  4. Study sites revised (75)v4
  5. Study sites revised (75)v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 65 to 75
    • Start date changed from estimate of Aug 5, 2025 to Aug 15, 2025
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
269 trials monitored
See 14 trials at risk
Diabetes
5,133 trials monitored
See 238 trials at risk
Type 2 Diabetes
2,254 trials monitored
See 117 trials at risk
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.
Trial Details
NCT Number NCT07112339
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2
Related terms Diabetes Mellitus, Type 2
Enrollment 586 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov